Ovid Therapeutics (OVID) Competitors $1.06 +0.01 (+0.95%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends OVID vs. CMPS, MRSN, ETON, ACIU, FATE, IMMP, ITOS, ATYR, ELDN, and TNYAShould you be buying Ovid Therapeutics stock or one of its competitors? The main competitors of Ovid Therapeutics include COMPASS Pathways (CMPS), Mersana Therapeutics (MRSN), Eton Pharmaceuticals (ETON), AC Immune (ACIU), Fate Therapeutics (FATE), Immutep (IMMP), iTeos Therapeutics (ITOS), Atyr PHARMA (ATYR), Eledon Pharmaceuticals (ELDN), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. Ovid Therapeutics vs. COMPASS Pathways Mersana Therapeutics Eton Pharmaceuticals AC Immune Fate Therapeutics Immutep iTeos Therapeutics Atyr PHARMA Eledon Pharmaceuticals Tenaya Therapeutics COMPASS Pathways (NASDAQ:CMPS) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, community ranking, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Which has better valuation and earnings, CMPS or OVID? Ovid Therapeutics has higher revenue and earnings than COMPASS Pathways. Ovid Therapeutics is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCOMPASS PathwaysN/AN/A-$118.46M-$2.20-1.91Ovid Therapeutics$631.70K119.16-$52.34M-$0.47-2.26 Is CMPS or OVID more profitable? COMPASS Pathways has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -5,142.56%. Ovid Therapeutics' return on equity of -39.24% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets COMPASS PathwaysN/A -63.85% -51.97% Ovid Therapeutics -5,142.56%-39.24%-26.19% Do analysts recommend CMPS or OVID? COMPASS Pathways presently has a consensus price target of $33.60, suggesting a potential upside of 700.00%. Ovid Therapeutics has a consensus price target of $4.04, suggesting a potential upside of 281.13%. Given COMPASS Pathways' stronger consensus rating and higher possible upside, analysts clearly believe COMPASS Pathways is more favorable than Ovid Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score COMPASS Pathways 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Ovid Therapeutics 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 Do insiders & institutionals have more ownership in CMPS or OVID? 46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by insiders. Comparatively, 13.3% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, CMPS or OVID? COMPASS Pathways has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Does the media refer more to CMPS or OVID? In the previous week, Ovid Therapeutics had 2 more articles in the media than COMPASS Pathways. MarketBeat recorded 4 mentions for Ovid Therapeutics and 2 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.36 beat Ovid Therapeutics' score of 1.01 indicating that COMPASS Pathways is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment COMPASS Pathways 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ovid Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor CMPS or OVID? Ovid Therapeutics received 294 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 80.00% of users gave COMPASS Pathways an outperform vote while only 70.80% of users gave Ovid Therapeutics an outperform vote. CompanyUnderperformOutperformCOMPASS PathwaysOutperform Votes6080.00% Underperform Votes1520.00% Ovid TherapeuticsOutperform Votes35470.80% Underperform Votes14629.20% SummaryOvid Therapeutics beats COMPASS Pathways on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaAI Crypto Tool Could Send One Coin SOARING…The #1 AI Coin to Buy Rapid growth predicted for little-known AI crypto projectDiscover our #1 crypto pick before it's too late. Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OVID vs. The Competition Export to ExcelMetricOvid TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.27M$6.85B$5.14B$9.31BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-2.2610.75135.1817.54Price / Sales119.16287.861,228.03140.34Price / CashN/A56.6540.6537.95Price / Book0.855.394.884.92Net Income-$52.34M$152.04M$118.97M$225.78M7 Day Performance-2.75%-4.32%15.73%-1.58%1 Month Performance1.92%2.80%15.69%6.67%1 Year Performance-68.55%17.30%34.73%22.48% Ovid Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OVIDOvid Therapeutics4.4901 of 5 stars$1.06+1.0%$4.04+281.1%-69.2%$75.27M$631,695.00-2.2660Positive NewsGap DownCMPSCOMPASS Pathways2.9382 of 5 stars$4.80+2.8%$30.67+538.9%-47.5%$328.42MN/A-2.12120Short Interest ↓Positive NewsMRSNMersana Therapeutics4.4297 of 5 stars$2.61+3.2%$6.00+129.9%-1.0%$322.41M$36.85M-4.56150Positive NewsGap UpETONEton Pharmaceuticals2.0676 of 5 stars$12.29-4.0%$15.00+22.1%+184.0%$317.57M$31.64M0.0020ACIUAC Immune2.6486 of 5 stars$3.18+1.0%$12.00+277.4%-25.0%$314.63M$16.48M0.00140Positive NewsFATEFate Therapeutics3.7051 of 5 stars$2.76+4.2%$6.75+144.6%-37.7%$314.34M$63.53M0.00550Short Interest ↑Gap UpIMMPImmutep1.5604 of 5 stars$2.14+2.4%$8.50+297.2%-14.5%$311.28M$5.14M0.002,021News CoverageGap UpITOSiTeos Therapeutics3.5971 of 5 stars$8.38+0.7%$31.50+275.9%-29.1%$306.16M$35M-2.6490ATYRAtyr PHARMA2.6077 of 5 stars$3.62+7.7%$19.25+431.8%N/A$303.86M$350,000.00-3.8756ELDNEledon Pharmaceuticals3.1299 of 5 stars$5.01+8.9%$16.00+219.4%+196.1%$299.30MN/A-2.3310Short Interest ↓Positive NewsHigh Trading VolumeTNYATenaya Therapeutics4.0363 of 5 stars$3.77+5.3%$17.33+359.8%-32.2%$298.66MN/A-2.71110News CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies CMPS Alternatives MRSN Alternatives ETON Alternatives ACIU Alternatives FATE Alternatives IMMP Alternatives ITOS Alternatives ATYR Alternatives ELDN Alternatives TNYA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OVID) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
